Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Mephenytoin
Drug ID BADD_D01386
Description Mephenytoin is used for the treatment of refractory partial epilepsy. Mephenytoin is a solid. This compound belongs to the phenylhydantoins. These are heterocyclic aromatic compounds containing an imiazolidinedione moiety substituted by a phenyl group. Mephenytoin is known to target sodium channel protein type 5 subunit alpha. Cytochrome P450 2C19, Cytochrome P450 2C8, Cytochrome P450 2C9, Cytochrome P450 2B6, Cytochrome P450 1A2, and Cytochrome P450 2D6 are known to metabolize mephenytoin. Mephenytoin is a hydantoin-derivative anticonvulsant used to control various partial seizures. Mephenytoin and oxazolidinedione derivatives are associated with higher incidences of blood dyscrasias compared to other anticonvulsants.
Indications and Usage For the treatment of refractory partial epilepsy.
Marketing Status Discontinued
ATC Code N03AB04
DrugBank ID DB00532
KEGG ID D00375
MeSH ID D008617
PubChem ID 4060
TTD Drug ID D07RGW
NDC Product Code Not Available
Synonyms Mephenytoin | 5-Ethyl-3-Methyl-5-Phenylhydantoin | 5 Ethyl 3 Methyl 5 Phenylhydantoin | Mefenetoin | Methoin | Methyl Phenetoin | Phenetoin, Methyl | Phenantoin | Mesantoin
Chemical Information
Molecular Formula C12H14N2O2
CAS Registry Number 50-12-4
SMILES CCC1(C(=O)N(C(=O)N1)C)C2=CC=CC=C2
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Adverse drug reactionCytochrome P450 2B1P00176Not Available3748010; 3514607; 7935340
Adverse drug reactionCytochrome P450 2C19P33261Not Available11334262; 15258107; 9224780; 7640152; 2206791; 10417492; 11694260; 11956668; 11046127; 7194443; 9222176; 1733741; 11929404; 15963082; 11719736
Adverse drug reactionCytochrome P450 2B6P20813T117933748010; 3514607; 7935340; 14534519; 16815319; 15961986
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Irritability19.04.02.013; 08.01.03.011--
Jaundice23.03.03.030; 09.01.01.004; 01.06.04.004--Not Available
Leukocytosis01.02.01.002--
Leukopenia01.02.02.001--Not Available
Lymphadenopathy01.09.01.002--Not Available
Lymphoma16.20.01.001; 01.12.01.001--Not Available
Monocytosis01.02.01.004--Not Available
Nausea07.01.07.001--
Nephrotic syndrome20.05.01.002--
Nervousness19.06.02.003--Not Available
Neutropenia01.02.03.004--Not Available
Non-Hodgkin's lymphoma01.17.01.001; 16.35.01.001--Not Available
Nystagmus17.02.02.006; 06.05.02.006--
Oedema14.05.06.010; 08.01.07.006--Not Available
Osteoarthritis15.01.04.001--Not Available
Pancytopenia01.03.03.003--Not Available
Photophobia17.17.02.006; 06.01.01.004--
Pulmonary fibrosis22.01.02.006--
Purpura24.07.06.005; 23.06.01.004; 01.01.04.003--
Rash23.03.13.001--Not Available
Rash maculo-papular23.03.13.004--
Rash morbilliform23.03.13.005--Not Available
Rash scarlatiniform23.03.13.006--Not Available
Seizure17.12.03.001--
Somnolence19.02.05.003; 17.02.04.006--
Stevens-Johnson syndrome11.07.01.005; 10.01.03.020; 23.03.01.007; 12.03.01.014--
Systemic lupus erythematosus23.03.02.006; 15.06.02.003; 10.04.03.004--Not Available
Tension19.06.02.005--Not Available
Thrombocytopenia01.08.01.002--Not Available
Toxic epidermal necrolysis12.03.01.015; 10.01.01.006; 11.07.01.006; 23.03.01.008--
The 2th Page    First    Pre   2 3    Next   Last    Total 3 Pages